This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Thursday, August 6, 2015
HOLKIRA PAK/Nova Scotia - ‘Second shot at life’: N.S. government to cover cost of new Hepatitis C drug
AbbVie drugs are also licensed in the U.S., where they are known as Viekira Pak.
‘Second shot at life’: N.S. government to cover cost of new Hepatitis C drug
HALIFAX – Hepatitis C patients in Nova Scotia can expect some good news – the province will soon cover the cost of a new drug that has a high success rate in treating the disease.
HOLKIRA PAK is a combination of medications that directly inhibits and kills the Hepatitis C virus, according to Dr. Lisa Barrett, an infectious disease physician with Nova Scotia Health Authority.
No comments:
Post a Comment